Mysore/Mysuru: Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, has announced that its subsidiary, Jubilant Generics Limited (Jubilant), has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of Rs. 4,700 per vial of 100 mg (lyophilized injection). 

The Company will make the drug available to over 1,000 Hospitals providing COVID-19 treatment in India through its distribution network. 

In order to increase accessibility of ‘JUBI-R’ to patients below the poverty line and to frontline paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programmes in India aimed at distribution of the drug.

It may recalled that remdesivir initially was being sold in the black market at exorbitant prices but with more Pharmacy company producing this drug this menace is expected to stop. The drug now is being manufactured by two pharmaceutical company Cipla and Hetro drugs. Now Jubilant too will be producing it. In the coming month another pharmaceutical company Mylan is also expected to to launch their version of remdesivir.